Janux reports ~$304M cash; JANX007 interim data show PSA drops 31-67% in 4/5 patients

Janux Therapeutics, Inc.

Preliminary cash, equivalents, and short-term investments ~$304.1M as of June 30, 2023.
JANX007 Phase 1a: 4 of 5 patients at flat doses (100-300µg) achieved PSA reductions of 31-67%.
No dose-limiting toxicities; CRS Grade 1-2 only in patients with PSA reductions; no Grade 3 CRS.
PK shows prolonged TRACTr exposure and lack of TCE accumulation, consistent with tumor activation.
Development moving into step-dosing and dose optimization to enhance efficacy with manageable safety.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.